Ask AI
ProCE Banner Activity

The Antiviral Angle: Leveraging the Full CMV Armamentarium

Podcast Episodes

Listen in as Dr Marcus Pereira discusses designing cytomegalovirus (CMV) antiviral regimens for high-risk kidney transplant recipients to mitigate the impact of infection while minimizing drug toxicities.

Released: August 21, 2025

Share

Provided by

Provided by Clinical Care Options, LLC, in collaboration with ProCE and in partnership with the American Kidney Fund

ProCE Banner
ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Merck & Co., Inc., Rahway, NJ, USA

Partners

American Kidney Fund

ProCE Banner

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Update clinical pathways for CMV prevention in high-risk kidney transplant recipients based on the latest clinical data

  • Design antiviral regimens for high-risk kidney transplant recipients to mitigate the impact of CMV on patient outcomes

  • Select antivirals for CMV prevention in kidney transplant recipients to minimize the impact of drug toxicities

Disclosure

Primary Author

Marcus Pereira, MD, MPH, FAST: consultant/advisor/speaker: Kamada, Synklino.